APOE and atherosclerosis: Treatment of apolipoprotein E-deficient (ApoE−/−) mice with FGF-21 reduced atherosclerosis formation by increasing adiponectin expression and inhibiting ER stress, NLRP3 inflammasome activation, and factor-associated suicide (FAS) signaling [31–33].